Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...

Novo Nordisk has gone ... like heart failure and kidney disease – as it tries to stay ahead of rivals like Eli Lilly. Demand for its semaglutide-based therapies Ozempic for diabetes and Wegovy ...

CP: When did Novo Nordisk (manufacturer of Ozempic and Wegovy ... heart attacks and strokes and reduce the rates of diabetic kidney disease and are helpful for people with obstructive sleep ...